

IMPACT FACTOR 3.4

Indexed in: PubMed



an Open Access Journal by MDPI

Recent Advances in Precision Medicine: Personalized Therapy, Drug **Delivery and Nanomedicine**

Guest Editors:

Prof. Dr. Liang Cheng

Legorreta Cancer Center at Brown University, Departments of Pathology and Surgery/Urology, Brown University Warren Alpert Medical School, Providence, RI, USA

Dr. Benedito A. Carneiro

Legorreta Cancer Center at Brown University, Division of Hematology/Oncology, The Warren Alpert Medical School, Providence, RI, USA

Dr. Chong-Xian Pan

Brigham and Women's Hospital. Harvard Medical School, Boston. MA. USA

Deadline for manuscript submissions:

15 November 2024



Dear Colleagues.

Personalized therapy is an emerging research area for disease treatment taking into account individual difference in genes, environment and lifestyles.

We hope to review the recent advances and upcoming technologies that will define how we can provide personalized treatment supported by individual patient or tumor molecular features or tailored to specific patient populations through targeted drug delivery. This Special Issue will cover established, new, and upcoming potential drugs, novel diagnostic modalities and therapeutic strategies, genomic discovery, nanomedicine, and cuttingedge technologies employed at all stages of target and drug discovery, validation, and delivery. It will also explore the role of machine learning in refining the understanding of mechanisms of resistance and signaling within complex pathophysiological systems.

We invite established investigators to contribute with original research and review articles. The submission deadline is May 1, 2023.

Sincerely,

Prof. Dr. Liang Cheng Dr. Benedito A. Carneiro Dr. Chong-xian Pan Guest Editors





IMPACT FACTOR 3.4





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

 Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
Division of Hematologic Malignancies and Cellular Therapy, Duke University,

Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous*))

Contact Us